HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Prognosis of Patients With de novo Acute Myeloid Leukemia Resistant to Initial Induction Chemotherapy.

AbstractBACKGROUND:
Initial induction chemotherapy is critical for patients with newly diagnosed de novo acute myeloid leukemia (AML). The aim of the present study was to analyze the factors affecting the outcome of patients with AML who failed to initial chemotherapy.
MATERIALS AND METHODS:
We retrospectively analyzed clinical data of 311 adults with de novo AML.
RESULTS:
Compared with 179 patients showing complete remission (CR), 132 patients who failed to achieve CR were older with poorer prognostic stratification, higher proportion of FLT3-ITD mutations, higher expression rates of CD9, lower expression rates of cMPO and CD64 and poorer overall survival (OS). The 2-year OS rate of the non-CR groups was inferior to that of the CR groups (28.3% versus 53.3%, P < 0.001). However, there was no dramatic difference in 2-year OS rate between initial and reinduction chemotherapy if patients achieved a same remission status. The 2-year OS rate significantly improved following allogeneic hematopoietic cell transplant in patients who failed to initial treatment. The survival of patients with similar remission status was affected by FLT3-ITD mutation instead of CD9(+) expression.
CONCLUSIONS:
Initial induction failure or poorer prognostic stratification seriously affected the survival of patients with de novo AML. The allogeneic hematopoietic cell transplant is an alternative strategy to improve the survival of patients resistant to initial treatment.
AuthorsSijing Wu, Shijia Yang, Li Zhu, Ying Wang, Yicheng Zhang, Jianfeng Zhou, Dengju Li
JournalThe American journal of the medical sciences (Am J Med Sci) Vol. 351 Issue 5 Pg. 473-9 (05 2016) ISSN: 1538-2990 [Electronic] United States
PMID27140705 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2016 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved.
Topics
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • China (epidemiology)
  • Hematopoietic Stem Cell Transplantation (statistics & numerical data)
  • Humans
  • Induction Chemotherapy (statistics & numerical data)
  • Leukemia, Myeloid, Acute (diagnosis, mortality, therapy)
  • Middle Aged
  • Prognosis
  • Remission Induction
  • Retrospective Studies
  • Survival Rate
  • Treatment Outcome
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: